CYP2A13 - cytochrome P450 family 2 subfamily A member 13 Gene

Also Known as CPAD; CYP2A; CYPIIA13

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 1553

About CYP2A13

Cytogenetic location: 19q13.2 Genomic coordinates (GRCh38): 19:41,088,451-41,096,195 (from NCBI)

This gene has 1 transcript (splice variant), 114 orthologues and 15 paralogues. Restricted expression toward liver (RPKM 9.1).

Summary

This gene encodes a member of the Cytochrome P450 superfamily of Enzymes. The Cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of Cholesterol, Steroids and Other lipids. This protein localizes to the endoplasmic reticulum. Although its endogenous substrate has not been determined, it is known to metabolize 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a major nitrosamine specific to tobacco. This gene is part of a large cluster of Cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. [provided by RefSeq, Jul 2008]

CYP2A13 Products (1)

mRNA Protein Name
NM_000766.5 NP_000757.2 cytochrome P450 2A13

Gene Ontology

  • Molecular Function
Molecular Function GO Annotation Evidence References Source
enables heme binding IDA
IDA: Inferred from direct assay
17428784 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

CYP2A13 Protein Structure

p450

p450: Cytochrome P450 (34 - 490)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 494 a.a.
Protein Preferred Names Protein Names

cytochrome P450 2A13

  • cytochrome P450, family 2, subfamily A, polypeptide 13

Related Diseases

Diseases Alias
Acetaminophen Metabolism
Lung Cancer

  • Lung Carcinoma

  • Non-Small Cell Lung Carcinoma

  • Lung Cancer, Susceptibility To

  • Lung Cancer, Protection Against

  • Adenocarcinoma Of Lung, Somatic

  • Adenocarcinoma Of Lung, Response To Tyrosine Kinase Inhibitor In

  • Nonsmall Cell Lung Cancer

  • Lung Neoplasm

  • Carcinoma Of Lung

  • Lung Non-Small Cell Carcinoma

  • Non-Small Cell Lung Cancer

  • Nsclc

  • Lung Neoplasms

  • Malignant Neoplasm Of Lung

  • Alveolar Cell Carcinoma

  • Nonsmall Cell Lung Cancer, Somatic

  • Nonsmall Cell Lung Cancer, Response To Tyrosine Kinase Inhibitor In

  • Nonsmall Cell Lung Cancer, Susceptibility To

  • Lung Cancer, Somatic

  • Lung Cancer, Resistance To

  • Cancer Of Lung

  • Cancer Of Bronchus

  • Cancer Of The Lung

  • Lung Malignancies

  • Lung Malignant Tumors

  • Malignant Lung Tumor

  • Malignant Tumor Of Lung

  • Pulmonary Cancer

  • Pulmonary Carcinoma

  • Pulmonary Neoplasms

  • Respiratory Carcinoma

  • LNCR

  • Adenocarcinoma Of Lung

  • Neoplasm Of Lung

  • Cancer Lung

  • Carcinoma Non-Small Cell Lung

  • Carcinoma, Non-Small-Cell Lung

  • Lung Cancers

  • Lung Carcinomas

  • Cancer, Lung

  • Cancer, Lung, Non-Small Cell

  • Primary Malignant Neoplasm Of Lung

  • Bronchioloalveolar Adenocarcinoma
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Approval
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-B1178 Cotinine Agonist 99.98% Unkown

Pre-clinical Phase

Bioactive Molecules (3)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-N8382 Chalepensin Inhibitor 98.98% Unkown
HY-W067695 Octahydrocoumarin Inhibitor 99.87% Unkown
HY-RS03453 CYP2A13 Human Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Rattus norvegicus CYP2A13 RGD RGD:2463